The National Lipid Association strives to champion issues of Clinical Lipidology for its members and for practitioners in the United States and internationally. In this role, the NLA has authored and endorsed various expert statements on issues affecting Lipidology. The following documents are evidence-based statements representing the pertinent issues for the practice of lipid management in clinical medicine.
On May 7, the decision was made to halt a late-stage trial of dalcetrapib, an experimental cholesterol drug intended to boost high density lipoprotein-cholesterol (HDL-C). A late-stage study, the dal-OUTCOMES Phase III trial, showed that dalcetrapib was not working effectively. The link above provides the joint response from the European Atherosclerosis Society (EAS), International Atherosclerosis Society (IAS) and the National Lipid Association (NLA).